Analysts expect that DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) will report earnings of ($0.25) per share for the current quarter, Zacks reports. Zero analysts have made estimates for DelMar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.39). DelMar Pharmaceuticals reported earnings per share of ($0.17) in the same quarter last year, which would indicate a negative year over year growth rate of 47.1%. The company is expected to report its next earnings report on Tuesday, September 12th.

According to Zacks, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.97) to ($0.77). For the next fiscal year, analysts forecast that the company will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.09) to ($0.65). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover DelMar Pharmaceuticals.

Several brokerages have issued reports on DMPI. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of DelMar Pharmaceuticals in a research note on Friday, June 23rd. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of DelMar Pharmaceuticals in a research note on Tuesday, May 30th. Finally, Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Tuesday, August 8th.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new stake in shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 13.84% of the stock is currently owned by institutional investors.

DelMar Pharmaceuticals (NASDAQ:DMPI) traded down 8.09% on Friday, reaching $1.25. The company’s stock had a trading volume of 63,532 shares. DelMar Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $7.54. The firm has a 50-day moving average of $1.81 and a 200 day moving average of $2.89.

TRADEMARK VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.